Dr Rasha Al-Lamee is an Interventional Cardiology Consultant at Imperial College Healthcare NHS Trust and a Reader at the National Heart and Lung Institute within Imperial College London. She is a British Heart Foundation intermediate clinical research fellow and clinical trialist with expertise in stable coronary artery disease, coronary intervention, invasive physiology and invasive intravascular imaging.

She leads a research group with a focus on clinical trials that impact the care of patients with cardiovascular disease. She believes in rigorous testing of clinical practice and the use of evidence-based medicine in all aspects of medical care. 

She designed and led the only placebo-controlled trials of coronary angioplasty, ORBITA and ORBITA-2, published in The Lancet and The New England Journal of Medicine respectively. She is also the chief investigator of the ORBITA-STAR, ORBITA-COSMIC and ORBITA-FIRE trials and has over 130 peer-reviewed publications and a h-index of 36. She is actively involved in the development and recruitment for many multi-centre international clinical trials.

She is a deputy editor at EuroIntervention and an associate editor at the European Heart Journal. She is the NIHR CRN North West London Cardiovascular speciality lead and co-head of the cardiovascular theme of the Imperial Biomedical Research Centre. She is Deputy Director and Phase 1b lead of Medicine at Imperial College London.